MARKET WIREBenzinga • 1d ago
LightSolver and Why AI May Outrun the GPU (NASDAQ: CLGN)Benzinga report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
Why CLGN Stock slipped -1.33% Today — RQD Quant Desk Flash
$4.08 -1.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.06
CollPlant Biotechnologies Ltd (CLGN) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $11.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CLGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.08 (-1.33% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLGN ranks #450 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CLGN compare to CUPR and RGNT in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M) and RGNT (Regentis Biomaterials Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.6M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CLGN?
▼
Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.06 (-0.43%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLGN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY CLGN SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (22% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.91-0.8% Next Q
33
Q2 (-2Q)Grade E$3.88+0.5% Next Q
36
Q3 (-1Q)Grade E$3.90+4.6% Next Q
38
CurrentGrade D-$4.08-7.2% Hist 90D α
41
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CLGN Turnaround Squeeze
While CLGN currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.74) and Max Pain ($4.28) forces dealer call-delta covering toward $24.04.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CLGN Stock slipped -1.33% Today — RQD Quant Desk Flash
CollPlant Biotechnologies Ltd (CLGN) slipped -1.33% to $4.08, trading at 7% of its 52-week range ($2.64 – $22.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($2.64 – $22.9) with RSI-14 at 54.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.08 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 64.8% gross margin and $0 annual free cash flow.
Live CLGN Headlines & Catalysts
MARKET WIREkalkine.ca • 1d ago
Is CollPlant Biotechnologies (NASDAQ:CLGN) Really Up 13.11% on a Capital Tag and Only 77,558 Shares?kalkine.ca report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A 10% stockholder proposes selling 15,550 CollPlant (CLGN) shares.Stock Titan report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
CollPlant Biotechnologies Ltd. announced that it has received $3.699986 million in fundingwww.marketscreener.com report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPR Newswire • 1d ago
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENTPR Newswire report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
An equity-and-warrant offering has $0 left to sell at CollPlant (CLGN).Stock Titan report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session - Mobile-health Network (NASDAQ:MNDR), XORTX ThBenzinga report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
CATALYSTkalkine.ca • 2d ago
Which of Mobile-health Network Solutions (NASDAQ:MNDR), Greenland Mines (NASDAQ:GRML), CollPlant Biotechnologies (NASDAQ:CLGN), Picard Medical (NYSEAMERICAN:PMI) or FIGS (NYSE:FIGS) Posted the Biggest Gain on Monday's Top Gainers Lkalkine.ca report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 5d ago
Reported Earlier: CollPlant Subsidiary LightSolver Signs Multi-Year Israel Defense Ministry Agreement For Photonic Computing, Secures Initial 12-Month Order In Defense Market With Estimated $5B Annual TAM, 15% CAGRCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced that its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing and developer of the Laser Processing Unit (LPU)™, has
MARKET WIREYahoo • 5d ago
LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing TechnologyThe Israel Ministry of Defense Engagement Strengthens LightSolver’s Position in the Emerging Photonic Computing Market for Defense Applications, Estimated at Up to $5 Billion AnnuallyRehovot, Israel, Oct. 29, 2026 (GLOBE
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLGN)
- ✓Walkthrough of CLGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CLGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.39%🛡️ HOLDING TREND SUPPORT
2026-11-03O $4.40H $4.40L $4.08C $4.08VOL 44.3K
RES: $12.56SUP: $3.57SMA50: $3.74SMA200: $5.00
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CLGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +360.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CLGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CLGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLGN)
Health Care Rank #450 of 1015
⚔️ CUPR vs CLGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CLGN vs. CUPR, RGNT, HSCS, LFWD)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, CollPlant Biotechnologies Ltd (CLGN) ranks #450 by composite RQD confidence (41/100, grade D-) and #876 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, CLGN leads on earnings valuation at N/A trailing P/E, while CLGN leads on capital efficiency and profitability with -35.0% ROIC and 64.8% gross margin. CLGN currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CLGN
ACTIVE
CollPlant Biotechnologies Ltd | D- | 41/100 | — | 64.8% | -35.0% | -1.33% | $11.9M | Benchmark Subject |
| CUPR Cuprina Holdings (Cayman) Limited (Class A) | E | 21/100 | — | -1.3% | -35.0% | +3.96% | $13.5M | /cupr-vs-clgn → |
| RGNT Regentis Biomaterials Ltd. | E | 31/100 | — | — | -35.0% | 0.00% | $9.6M | /rgnt-vs-clgn → |
| HSCS HeartSciences Inc. | D- | 38/100 | — | 59.1% | -35.0% | -9.67% | $16.0M | /hscs-vs-clgn → |
| LFWD Lifeward Ltd. | E | 32/100 | — | 96.0% | -35.0% | +1.82% | $16.9M | /lfwd-vs-clgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001631487 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported GAAP revenue of $2.4M (+360.4% vs. FY2024 revenue of $515.0K , and -78.4% cumulative change since FY2023) , GAAP net income of -$11.5M, operating cash flow of -$9.4M, and free cash flow of -$9.4M (+35.2% YoY). On the balance sheet, CLGN closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.4M | -$11.5M | -$9.4M | -$9.4M | $10.8M | — |
| FY2024 (FY) | 2024-12-31 | $515.0K | -$16.6M | -$14.1M | -$14.6M | $18.7M | — |
| FY2023 (FY) | 2023-12-31 | $11.0M | -$7.0M | -$2.8M | -$2.8M | — | — |
3. CLGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.08 (-1.33% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLGN ranks #450 in composite RQD confidence.
How does CLGN compare to CUPR and RGNT in the Health Care sector?
Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M) and RGNT (Regentis Biomaterials Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.6M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CLGN?
Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CLGN trading relative to its 50-day, 200-day, and 52-week technical levels?
CLGN last traded at $4.08 (-1.33% on volume of 40,499 shares), positioning the stock +9.09% above its 50-day simple moving average ($3.74) and -18.40% below its 200-day simple moving average ($5.00). Across its 52-week range of $2.64 to $22.90, CLGN sits at the 7.1% percentile with a 14-day RSI of 54.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.57 to $4.59).
ROARABLE RATING BRIEF • RQD 41/100 (D-)
✓ SEC XBRL & RQD VERIFIED
CLGN — CollPlant Biotechnologies Ltd: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
CollPlant Biotechnologies Ltd (CLGN) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.08 (-1.33% 1D, market capitalization $11.9M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 64.8%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
CollPlant Biotechnologies Ltd (CLGN) is listed on NASDAQ and classified under the Health Care sector and Industrial Specialties industry,. Reported revenue was $2.4M in FY 2025, $0.5M in FY 2024, and $11.0M in FY 2023. Gross margin is reported at 64.8%, while operating margin is -60%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported $2.4M in annual revenue (up from $515.0K in FY2024, +360.4% YoY) and -$11.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($11.0M revenue, -$7.0M net income) through FY2025, CLGN scaled operating cash flow to -$9.4M and free cash flow to -$9.4M, backed by $10.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.64 – $22.90 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector-level information is the classification as Health Care / Industrial Specialties. Investors should treat the absence of mapped supply-chain links as a gap in the analysis rather than evidence of independence.
- Key Question #1: Can CLGN sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.4M and free cash flow of -$9.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CLGN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CLGN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for CollPlant Biotechnologies Ltd (CLGN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Benzinga • 1d ago
LightSolver and Why AI May Outrun the GPU (NASDAQ: CLGN) Benzinga report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Is CollPlant Biotechnologies (NASDAQ:CLGN) Really Up 13.11% on a Capital Tag and Only 77,558 Shares? kalkine.ca report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 10% stockholder proposes selling 15,550 CollPlant (CLGN) shares. Stock Titan report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
CollPlant Biotechnologies Ltd. announced that it has received $3.699986 million in funding www.marketscreener.com report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 1d ago
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT PR Newswire report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
An equity-and-warrant offering has $0 left to sell at CollPlant (CLGN). Stock Titan report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session - Mobile-health Network (NASDAQ:MNDR), XORTX Th Benzinga report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST kalkine.ca • 2d ago
Which of Mobile-health Network Solutions (NASDAQ:MNDR), Greenland Mines (NASDAQ:GRML), CollPlant Biotechnologies (NASDAQ:CLGN), Picard Medical (NYSEAMERICAN:PMI) or FIGS (NYSE:FIGS) Posted the Biggest Gain on Monday's Top Gainers L kalkine.ca report covering CollPlant Biotechnologies Ltd (CLGN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CLGN Bull vs. Bear Conversation Board — What's Your Call at $4.08?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLGN 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $5.13 (+23.9%)
📌 Pinned Debate Forensic balance sheet pillar (11/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest component of the rating and gross margin is 64.8%
Here is why I am bullish on CLGN here at $4.14: Forensic balance sheet pillar (11/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest component of the rating and gross margin is 64.8%.. Compare CLGN's -60.0% operating margin and -35.0% ROIC against the rest of Industrial Specialties. As long as cash conversion holds up, dips toward $3.93 are getting bought.
VolSurface_Trader 🐂 BULL
Both sides have a point here — CLGN's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $3.39 (-18.1%)
Spot @ $4.14 Revenue fell from $11.0M to $2.4M while operating losses persisted at -$11.5M and ROIC sits at -35%, alongside dilution signals from a
Revenue fell from $11.0M to $2.4M while operating losses persisted at -$11.5M and ROIC sits at -35%, alongside dilution signals from a $3.7M private placement and exhausted offering capacity.. Look at the math on CLGN: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $3.64 before getting long.